The FDA just approved a new pancreatic cancer pill. What's the list price for 30 days?

Drag to get close · ▲▼ to fine-tune

A 30-day supply of the new pancreatic cancer pill lists at $39,800, or about $477,000 a year. In the trial behind its approval, it raised median survival to 13.2 months from 6.7 months on chemotherapy. The company expects insurers to negotiate 20% to 30% off the list price.

The FDA cleared it roughly six months ahead of its own deadline. The pill blocks RAS proteins, which drive more than 90% of pancreatic cancers. It is the first medicine to target them broadly in this disease.

A new pancreatic cancer pill lists at $39,800 for a 30-day supply. That's about $477,000 a year.

Source: Revolution Medicines / FDA · checked Aug 2026